Even though MYCN represents a highly attractive therapeutic target in NB, as a transcription factor that lacks hydrophobic pockets which can be targeted by drug-like small molecules, it is still considered as being “undruggable” [20, 21]. The gene discussed is MYCN; the disease is neuroblastoma.